Eric Roberts Biography and Net Worth

Insider of CalciMedica

Mr. Roberts has 30 years of experience in the finance, investment and life sciences industry and has completed hundreds of financings and merger transactions. Mr. Roberts is currently Vice Chairman of the Board of CalciMedica Inc. He has served on the boards of a number of public and private life science companies. In 2012, Mr. Roberts co-founded the investment firm, Valence Life Sciences. Prior to Valence Life Sciences, Mr. Roberts managed the Caxton Advantage Life Sciences Fund which he co-founded in 2005. Prior to Caxton Advantage, he was Managing Director and Co-Head of the Global Healthcare Investment Banking Group at Lehman Brothers.

Mr. Roberts was also a Managing Director, Partner and founder of the Life Sciences Department at Dillon, Read & Co. Inc. which was ultimately merged into UBS. At UBS, Mr. Roberts ran the Life Sciences investment banking team. Earlier in his career, Mr. Roberts worked at the Citicorp Venture Capital (CVC) group. Mr. Roberts received a B.S. in Economics from the Wharton School of the University of Pennsylvania. He is also a Director of the Cary Institute for Ecosystem Studies, the Atlantic Salmon Federation and is a past Director of the American Museum of Fly Fishing.

What is Eric W. Roberts' net worth?: The estimated net worth of Eric W. Roberts is at least $24.82 thousand as of September 18th, 2025. Roberts owns 16,830 shares of CalciMedica stock worth more than $24,824 as of October 6th. This net worth approximation does not reflect any other assets that Roberts may own. Learn More about Eric W. Roberts' net worth.
How do I contact Eric W. Roberts?: The corporate mailing address for Roberts and other CalciMedica executives is 505 Coast Boulevard South, Suite 307, LA Jolla, CA, 92037. CalciMedica can also be reached via phone at 858-952-5500 and via email at [email protected]. Learn More on Eric W. Roberts' contact information.
Has Eric W. Roberts been buying or selling shares of CalciMedica?: Eric W. Roberts has not been actively trading shares of CalciMedica during the last ninety days. Most recently, on Thursday, September 18th, Eric W. Roberts bought 500 shares of CalciMedica stock. The stock was acquired at an average cost of $15.35 per share, with a total value of $7,675.00. Following the completion of the transaction, the insider now directly owns 16,830 shares of the company's stock, valued at $258,340.50. Learn More on Eric W. Roberts' trading history.
Who are CalciMedica's active insiders?: CalciMedica's insider roster includes A. Leheny (CEO), and Eric Roberts (Insider). Learn More on CalciMedica's active insiders.
Are insiders buying or selling shares of CalciMedica?: In the last twelve months, CalciMedica insiders bought shares 1 times. They purchased a total of 49,794 shares worth more than $199,176.00. The most recent insider tranaction occured on June, 25th when Director Fred A Middleton bought 49,794 shares worth more than $199,176.00. Insiders at CalciMedica own 28.3% of the company. Learn More about insider trades at CalciMedica.
Information on this page was last updated on 6/25/2026.

Eric W. Roberts Insider Trading History at CalciMedica

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/18/2025	Buy	500	$15.35	$7,675.00	16,830
9/15/2025	Buy	680	$13.40	$9,112.00	16,330
9/12/2025	Buy	1,000	$15.60	$15,600.00	15,650
9/9/2025	Buy	468	$15.75	$7,371.00	14,650
8/29/2025	Buy	160	$13.70	$2,192.00	14,181
8/28/2025	Buy	1,840	$14.30	$26,312.00	14,021
8/21/2025	Buy	701	$13.95	$9,778.95	12,181
8/20/2025	Buy	400	$13.60	$5,440.00	11,479
8/19/2025	Buy	200	$13.95	$2,790.00	11,079
8/15/2025	Buy	1,015	$14.50	$14,717.50	10,879
7/21/2025	Buy	300	$16.85	$5,055.00	9,564
7/18/2025	Buy	400	$14.40	$5,760.00	9,264
7/14/2025	Buy	1,300	$12.15	$15,795.00	8,864
7/9/2025	Buy	1,000	$8.00	$8,000.00	7,564
6/26/2025	Buy	900	$7.20	$6,480.00	6,564
6/11/2025	Buy	1,000	$9.25	$9,250.00	5,664
11/1/2024	Buy	10,666	$18.75	$199,987.50	32,941
8/23/2024	Buy	1,000	$17.85	$17,850.00	9,378
8/21/2024	Buy	1,000	$20.20	$20,200.00	8,978
6/27/2024	Buy	1,000	$16.10	$16,100.00	2,044
4/1/2024	Buy	149	$19.50	$2,905.50	7,328
11/6/2023	Buy	480	$15.60	$7,488.00	7,178
11/3/2023	Buy	640	$14.00	$8,960.00	3,317
8/25/2023	Buy	147	$15.90	$2,337.30	1,000
8/21/2023	Buy	350	$16.25	$5,687.50	710
6/26/2023	Buy	240	$18.50	$4,440.00	2,677
6/23/2023	Buy	100	$16.75	$1,675.00	3,237

Eric W. Roberts Buying and Selling Activity at CalciMedica

CalciMedica Company Overview

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Today's Range

Now: $1.49

$1.42

$1.61

50 Day Range

MA: $2.60

$1.54

$5.00

2 Week Range

Now: $1.49

$1.42

$36.00

Volume

168,415 shs

Average Volume

187,870 shs

Market Capitalization

$10.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76